F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity

Leukemia

Volumn 27, Issue 11, 2013, Pages 2139-2148

  Kruczynski, A ^a   Pillon, A ^a   Creancier L ^a   Vandenberghe, I ^a   Gomes, B ^a   Brel, V ^a   Fournier, E ^a   Annereau, J P ^a   Currie, E ^b   Guminski, Y ^a   Bonnet, D ^b   Bailly, C ^a   Guilbaud, N ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

antileukemic activity; apoptosis; combination therapy; senescence; spermine drug conjugate; targeted cytotoxic agent

Indexed keywords

ANTILEUKEMIC AGENT; BORTEZOMIB; CAMPTOTHECIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; F 14512; GEMCITABINE; NAVELBINE; PACLITAXEL; POLYAMINE; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CELL AGING; CELL STRAIN HL 60; CELL STRAIN U937; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LIFE EXTENSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENESCENCE; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CELL PROLIFERATION; CYTARABINE; DEOXYCYTIDINE; DOXORUBICIN; FETAL BLOOD; FLOW CYTOMETRY; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; PODOPHYLLOTOXIN; PYRAZINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887317353     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.108     Document Type: Article

References (34)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Eng J Med 1999; 341: 1051-1062. (Pubitemid 29451802)
2. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006; 107: 2099-2107. (Pubitemid 44665642)
3. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials. Cancer 2006; 107: 116-124. (Pubitemid 43939038)
4. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
5. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predicitive prognostic models for outcome. Cancer 2006; 106: 1090-1098.
6. Adema AD, Smid K, Losekoot N, Honeywell RJ, Verheul HM, Myhren F et al. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest New Drugs 2012; 30: 1908-1916.
7. Kean N, Freeman C, Swords R, Giles FJ. Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia. Expert Rev Hamatol 2013; 6: 9-24.
8. Annereau JP, Brel V, Dumontet C, Guminski Y, Imbert T, Broussas M et al. A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment. Leuk Res 2010; 34: 1383-1389.
9. Ballot C, Jendoubi M, Kluza J, Jonneaux A, Laine W, Formstecher P et al. Regulation by survivin of cancer cell death induced by F14512, a polyaminecontaining inhibitor of DNA topoisomerase II. Apoptosis 2012; 17: 364-376.
10. Barret JM, Kruczynski A, Vispé S, Annereau JP, Brel V, Guminski Y et al. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. Cancer Res 2008; 68: 9845-9853.
11. Brel V, Annereau JP, Vispé S, Kruczynski A, Bailly B, Guilbaud N. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II. Biochem Pharmacol 2011; 82: 1843-1852.
12. Gentry AC, Pitts SL, Jablonsky MJ, Bailly C, Graves DE, Osheroff N. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry 2011; 50: 3240-3249.
13. Kruczynski A, Vandenberghe I, Pillon A, Pesnel S, Goetsch L, Barret JM et al. Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system. Invest New Drugs 2011; 29: 9-21.
14. Chelouah S, Monod-Wissler C, Bailly C, Barret JM, Guilbaud N, Vispé S et al. An integrated Drosophilia model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II. PLoS One 2011; 6: e23597.
15. De Botton S, Berthon C, Bulabois CE, Prebet T, Vey N, Chevallier P et al. F14512 a novel polyamine-vectorized anti-cancer drug targeting topoisomerase II in adults patients with acute myeloid leukemia (AML): results from a Phase 1 study. EHA 17th Congress. 14-17 June 2012; Amsterdam.
16. Cré ancier L, Pillon A, Verdier J, Chansard N, Pourtau S, Vandenberghe I et al. Use of bioluminescence imaging and quantitative RT-PCR to monitor tumor progression and treatment response in orthotopic AML mouse models: Application to the targeted cytotoxic agent F14512. Eur J Cancer 2010; 8: 89.
17. Kruczynski A, Colpaert F, Tarayre J-P, Mouillard P, Fahy J, Hill BT. Preclinical in vivo antitumour activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 1998; 41: 437-447. (Pubitemid 28140706)
18. Plovins A, Alvarez AM, Ibanez M, Molina M, Nombela C. Use of fluorescein-dibeta-D galactopyranoside (FDG) and C12-FDG as substrates for beta-galactosidase detection by flow cytometry in animal, bacterial, and yeast cells. Appl Environ Microbiol 1994; 60: 4638-4641. (Pubitemid 24370848)
19. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.
20. Corbett TH, Veleriote FA, Demchik L, Polin L, Panchapor C, Pugh S et al. Preclinical anticancer activity of cryptophycin-8. J Exp Ther Oncol 1996; 1: 95-108. (Pubitemid 126740531)
21. Scatena CD, Kumer JL, Arbitrario JP, Howlett AR, Hawtin RE, Fox JA et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol 2010; 66: 881-888.
22. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tendem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918. (Pubitemid 27019637)
23. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P et al. Cooperating gene mutation in acute myeloid leukemia: a review of the literature. Leukemia 2008; 22: 915-931. (Pubitemid 351709343)
24. Chresta CM, Hicks R, Hartley JA, Souhami RL. Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxix concentrations of arabinosyl cytosine. Cancer Chemother Pharmacol 1992; 31: 139-145.
25. Lin TL, Levy MY. Acute myeloid leukemia: focus on novel therapeutic strategies. Clin Med Insights 2012; 6: 205-217.
26. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004; 23: 2919-2933. (Pubitemid 38638853)
27. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y et al. A senescencelike phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999; 59: 3761-3767. (Pubitemid 29381884)
28. Chiu CC, Li CH, Ung MW, Fuh TS, Cheng WL, Fang K. Etoposide (VP-16) elicits apoptosis following prolonged G2-M arrest in p53-mutated human non-small cell lung cancer cells. Cancer Lett 2005; 223: 249-258. (Pubitemid 40723603)
29. Mow BMF, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Curr Opin Oncol 2001; 13: 453-462. (Pubitemid 33027897)
30. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002; 62: 1876-1883. (Pubitemid 34408516)
31. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729-740. (Pubitemid 47312822)
32. Lin CI, Whang EE, Lorch JH, Ruan DT. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery 2012; 152: 1142-1149.
33. Knizhnik AV, Roos WP, Nikolova T, Quiros S, Tomaszowski KH, Christmann M et al. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One 2013; 8: e55665.
34. Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 2009; 69: 4150-4158.